Advertisement

Annals of Hematology

, Volume 97, Issue 9, pp 1663–1669 | Cite as

A higher percentage of cells with 13q deletion predicts worse outcome in Chinese patients with chronic lymphocytic leukemia carrying isolated 13q deletion

  • Yuqing Miao
  • Yi Miao
  • Ke Shi
  • Qian Sun
  • Si-Shu Zhao
  • Yi Xia
  • Shu-Chao Qin
  • Hai-Rong Qiu
  • Hui Yang
  • Hao Xu
  • Hua-Yuan Zhu
  • Jia-Zhu Wu
  • Wei Wu
  • Lei Cao
  • Li Wang
  • Lei Fan
  • Wei Xu
  • Jian-Yong Li
Original Article
  • 91 Downloads

Abstract

Previous studies showed that, in chronic lymphocytic leukemia (CLL) patients with isolated 13q deletion (13q-), those carrying higher percentage of leukemic cells with 13q- had more aggressive diseases. However, the prognostic value of the percentage of leukemic cells with 13q- in Chinese CLL patients with isolated 13q- remained to be determined. Using interphase fluorescence in situ hybridization (FISH), we identified 82 patients (25.4%) with isolated 13q deletion from a cohort of 323 untreated CLL patients. Among patients with isolated 13q deletion, cases of 13q- cells ≥ 80% (13q-H) had significantly shorter time to first treatment (TTT) than those of < 80% 13q- cells (13q-L) (median 11 vs. 92 months, p = 0.0016). A higher lymphocyte count (p = 0.0650) was associated with 13q-H, while other clinical, immunophenotypic, or molecular features did not differ between patients with 13q-H and 13q-L. Although 13q-H only showed marginal significance in multivariate analysis of TTT (hazards ratio 2.007; 95% confidence interval 0.975–4.129; p = 0.059), it helped refine the risk stratification based on Binet stage or immunoglobulin heavy chain variable gene (IGHV) status. In cases in Binet A or B stage, patients with 13q-H had a significantly shorter TTT (median TTT 18 months vs. undefined, p = 0.0101). And in IGHV mutated patients, 13q-H was also associated with reduced TTT (median TTT 13q-H. 18 months vs. 13q-L undefined, p = 0.0163). In conclusion, the prognosis of CLL patients with isolated 13q deletion was heterogeneous with 13q-H identifying patients with worse outcome.

Keywords

Chronic lymphocytic leukemia FISH 13q deletion Prognosis 

Notes

Authors’ contributions

J.Y.L, W.X, and Y.Q.M designed the study. Y.Q.M, Q.S, K.S, S.S.Z, Y.X, S.C.Q, H.R.Q, H.Y, H.X, H.Y.Z, J.Z.W, W.W, L.C, L.W, and L.F collected and analyzed the data. Y. M and Y.Q.M wrote the draft of the paper, and all authors contributed in writing and approved the final version of the manuscript.

Funding information

This study was supported by National Natural Science Foundation of China (30971296, 81170485, 81170488, 81370657, 81470328, 81500125, 81522001, 81570141), Project of National Key Clinical Specialty, the National Science & Technology Pillar Program (2014BAI09B12), and a project funded by Jiangsu Provincial Special Program of Medical Science (BL2014086).

Compliance with ethical standards

The study was approved by the Ethic Committee of the First Affiliated Hospital of Nanjing Medical University and conducted in accordance with the Declaration of Helsinki. Informed consent was provided by the subjects in the study.

Conflict of interest

The authors declare that they have no conflicts of interest.

Supplementary material

277_2018_3359_MOESM1_ESM.doc (54 kb)
ESM 1 (DOC 53 kb)

References

  1. 1.
    Puiggros A, Delgado J, Rodriguez-Vicente A, Collado R, Aventin A, Luno E, Grau J, Hernandez JA, Marugan I, Ardanaz M, Gonzalez T, Valiente A, Osma M, Calasanz MJ, Sanzo C, Carrio A, Ortega M, Santacruz R, Abrisqueta P, Abella E, Bosch F, Carbonell F, Sole F, Hernandez JM, Espinet B (2013) Biallelic losses of 13q do not confer a poorer outcome in chronic lymphocytic leukaemia: analysis of 627 patients with isolated 13q deletion. Br J Haematol 163(1):47–54.  https://doi.org/10.1111/bjh.12479 CrossRefPubMedGoogle Scholar
  2. 2.
    Nabhan C, Rosen ST (2014) Chronic lymphocytic leukemia: a clinical review. JAMA 312(21):2265–2276.  https://doi.org/10.1001/jama.2014.14553 CrossRefPubMedGoogle Scholar
  3. 3.
    Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, Dohner K, Bentz M, Lichter P (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343(26):1910–1916.  https://doi.org/10.1056/NEJM200012283432602 CrossRefPubMedGoogle Scholar
  4. 4.
    Hernandez JA, Rodriguez AE, Gonzalez M, Benito R, Fontanillo C, Sandoval V, Romero M, Martin-Nunez G, de Coca AG, Fisac R, Galende J, Recio I, Ortuno F, Garcia JL, de las Rivas J, Gutierrez NC, San Miguel JF, Hernandez JM (2009) A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia. Haematologica 94(3):364–371.  https://doi.org/10.3324/haematol.13862 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Dal Bo M, Rossi FM, Rossi D, Deambrogi C, Bertoni F, Del Giudice I, Palumbo G, Nanni M, Rinaldi A, Kwee I, Tissino E, Corradini G, Gozzetti A, Cencini E, Ladetto M, Coletta AM, Luciano F, Bulian P, Pozzato G, Laurenti L, Forconi F, Di Raimondo F, Marasca R, Del Poeta G, Gaidano G, Foa R, Guarini A, Gattei V (2011) 13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. Genes Chromosom Cancer 50(8):633–643.  https://doi.org/10.1002/gcc.20885 CrossRefPubMedGoogle Scholar
  6. 6.
    Van Dyke DL, Shanafelt TD, Call TG, Zent CS, Smoley SA, Rabe KG, Schwager SM, Sonbert JC, Slager SL, Kay NE (2010) A comprehensive evaluation of the prognostic significance of 13q deletions in patients with B-chronic lymphocytic leukaemia. Br J Haematol 148(4):544–550.  https://doi.org/10.1111/j.1365-2141.2009.07982.x CrossRefPubMedGoogle Scholar
  7. 7.
    Yang SM, Li JY, Gale RP, Huang XJ (2015) The mystery of chronic lymphocytic leukemia (CLL): why is it absent in Asians and what does this tell us about etiology, pathogenesis and biology? Blood Rev 29(3):205–213.  https://doi.org/10.1016/j.blre.2014.12.001 CrossRefPubMedGoogle Scholar
  8. 8.
    Marinelli M, Ilari C, Xia Y, Del Giudice I, Cafforio L, Della Starza I, Raponi S, Mariglia P, Bonina S, Yu Z, Yang W, Qiu L, Chan T, Piciocchi A, Kwong YL, Tse E, Li J, Guarini A, Xu W, Foa R (2016) Immunoglobulin gene rearrangements in Chinese and Italian patients with chronic lymphocytic leukemia. Oncotarget 7(15):20520–20531.  https://doi.org/10.18632/oncotarget.7819 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Xia Y, Fan L, Wang L, Gale RP, Wang M, Tian T, Wu W, Yu L, Chen YY, Xu W, Li JY (2015) Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans. Oncotarget 6(7):5426–5434.  https://doi.org/10.18632/oncotarget.3101 CrossRefPubMedGoogle Scholar
  10. 10.
    Qiu HX, Xu W, Cao XS, Zhou M, Shen YF, Xu YL, Sun XM, Liu Q, Wang R, Qiu HR, Wang JS, Li JY (2008) Cytogenetic characterisation in Chinese patients with chronic lymphocytic leukemia: a prospective, multicenter study on 143 cases analysed with interphase fluorescence in situ hybridisation. Leuk Lymphoma 49(10):1887–1892.  https://doi.org/10.1080/10428190802308710 CrossRefPubMedGoogle Scholar
  11. 11.
    Xu W, Li JY, Li L, Yu H, Shen QD, Fan L, Qiao C, Hong M, Qian SX, Qiu HX (2008) Fluorescent in situ hybridization with a panel of probes detects molecular cytogenetic abnormalities in patients with chronic lymphocytic leukemia. Zhonghua Yi Xue Za Zhi 88(36):2537–2540PubMedGoogle Scholar
  12. 12.
    Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the National Cancer Institute-working group 1996 guidelines. Blood 111(12):5446–5456.  https://doi.org/10.1182/blood-2007-06-093906 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Miao Y, Fan L, Wu YJ, Xia Y, Qiao C, Wang Y, Wang L, Hong M, Zhu HY, Xu W, Li JY (2016) Low expression of CD200 predicts shorter time-to-treatment in chronic lymphocytic leukemia. Oncotarget 7(12):13551–13562.  https://doi.org/10.18632/oncotarget.6948 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Wu YJ, Wang H, Liang JH, Miao Y, Liu L, Qiu HR, Qiao C, Wang R, Li JY (2016) Using the geometric mean fluorescence intensity index method to measure ZAP-70 expression in patients with chronic lymphocytic leukemia. Onco Targets Ther 9:797–805.  https://doi.org/10.2147/OTT.S94613 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Gerrie AS, Bruyere H, Chan MJ, Dalal CB, Ramadan KM, Huang SJ, Toze CL, Gillan TL (2012) Immunoglobulin heavy chain (IGH@) translocations negatively impact treatment-free survival for chronic lymphocytic leukemia patients who have an isolated deletion 13q abnormality. Cancer Genet 205(10):523–527.  https://doi.org/10.1016/j.cancergen.2012.05.011 CrossRefPubMedGoogle Scholar
  16. 16.
    Shanafelt TD, Witzig TE, Fink SR, Jenkins RB, Paternoster SF, Smoley SA, Stockero KJ, Nast DM, Flynn HC, Tschumper RC, Geyer S, Zent CS, Call TG, Jelinek DF, Kay NE, Dewald GW (2006) Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol 24(28):4634–4641.  https://doi.org/10.1200/JCO.2006.06.9492 CrossRefPubMedGoogle Scholar
  17. 17.
    Baliakas P, Hadzidimitriou A, Sutton LA, Rossi D, Minga E, Villamor N, Larrayoz M, Kminkova J, Agathangelidis A, Davis Z, Tausch E, Stalika E, Kantorova B, Mansouri L, Scarfo L, Cortese D, Navrkalova V, Rose-Zerilli MJ, Smedby KE, Juliusson G, Anagnostopoulos A, Makris AM, Navarro A, Delgado J, Oscier D, Belessi C, Stilgenbauer S, Ghia P, Pospisilova S, Gaidano G, Campo E, Strefford JC, Stamatopoulos K, Rosenquist R (2015) Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia 29(2):329–336.  https://doi.org/10.1038/leu.2014.196 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Yuqing Miao
    • 1
    • 2
    • 3
    • 4
  • Yi Miao
    • 1
    • 2
    • 3
  • Ke Shi
    • 1
    • 2
    • 3
  • Qian Sun
    • 1
    • 2
    • 3
  • Si-Shu Zhao
    • 1
    • 2
    • 3
  • Yi Xia
    • 1
    • 2
    • 3
  • Shu-Chao Qin
    • 1
    • 2
    • 3
  • Hai-Rong Qiu
    • 1
    • 2
    • 3
  • Hui Yang
    • 1
    • 2
    • 3
  • Hao Xu
    • 4
  • Hua-Yuan Zhu
    • 1
    • 2
    • 3
  • Jia-Zhu Wu
    • 1
    • 2
    • 3
  • Wei Wu
    • 1
    • 2
    • 3
  • Lei Cao
    • 1
    • 2
    • 3
  • Li Wang
    • 1
    • 2
    • 3
  • Lei Fan
    • 1
    • 2
    • 3
  • Wei Xu
    • 1
    • 2
    • 3
  • Jian-Yong Li
    • 1
    • 2
    • 3
  1. 1.Department of Hematology, The First Affiliated Hospital of Nanjing Medical UniversityJiangsu Province HospitalNanjingChina
  2. 2.Key Laboratory of Hematology of Nanjing Medical UniversityNanjingChina
  3. 3.Collaborative Innovation Center for Cancer Personalized MedicineNanjingChina
  4. 4.Department of HematologyThe First People’s Hospital of YanchengYanchengChina

Personalised recommendations